drugset / Trial / NCT04081363
Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
NaSingle-groupOpen-labelTreatment
Summary
With the pharmacokinetics (PK) of centanafadine currently being evaluated in adults. The PK of extended-release centanafadine may differ in children compared to adults due to physiological differences in the gastrointestinal tract. The information in this trial will support pediatric dose selection in future trials.
Timeline
- Start
- 2019-10-07
- Primary completion
- 2019-12-21
- Completion
- 2019-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Centanafadine | Small molecule | 55 mg | Oral |